Monitoring Microsatellite Instability (MSI) in Circulating Tumor DNA by Next-Generation DNA-seq.

Adam Deng,Jialiang Yang,Jidong Lang,Zheng Jiang,Weitao Wang,Dawei Yuan,Xishan Wang,Geng Tian
DOI: https://doi.org/10.1200/jco.2018.36.15_suppl.12025
IF: 45.3
2018-01-01
Journal of Clinical Oncology
Abstract:12025 Background: Microsatellite instability (MSI) is a useful predictive biomarker for prognosis of patients with phase II colorectal cancer and clinical benefit from cancer immunotherapy. Conventional MSI testing is commonly performed with tumor tissues by a fluorescent multiplex PCR-based method, consisting of six mononucleotide microsatellite makers. Recently, next generation DNA sequencing (NGS) has been developed for detection of MSI status in tumor tissues. However, we are still curious about whether we could accurately monitor MSI in ctDNA by NGS to achieve the non-invasive diagnosis. Methods: We collected plasma, matched tumor tissue and blood samples from 200 cancer patients. ctDNAs extracted from plasma and genomic DNAs extracted from tumor tissue and blood were used to perform MSI testing by conventional PCR methodand amplicon-based NGS. Six regular mononucleotide microsatellite makers (NR-27, NR-21, BAT-26, BAT-25, NR-24, MONO-27) were analyzed in two methods, and blood was compared as the normal control for MSI evaluation. MSI-H or MSI-L/MSS patients were primarily distinguished by conventional PCR method. Further we performed MSI detection in plasma, matched tumor tissue and blood by NGS and designed an algorithm for evaluating MSI status. Results: In 200 cancer patients, we primarily identified 13 patients with MSI-H (6.5%) and the others with MSS by conventional PCR method. Interestingly, we found that MSI testing in plasma was not performed by conventional PCR assay, namely that MSI could not be precisely monitored by conventional method. However, both MSI testing in plasma and in tumor tissue could be performed well by NGS. Compared the results of MSI testing in tumor tissue by two methods, there was high consistency. Importantly, we found that all 13 MSI-H patients were correctly identified by MSI testing in circulating tumor DNA(ctDNA), in concordance with the results of MSI testing in tumor tissue. The sensitivity of MSI testing was 100%. Conclusions: In our study, the MSI status of cancer patients could be accurately monitored in circulating tumor DNA(ctDNA) by amplicon-based NGS. It provides the possibility of non-invasive MSI testing for cancer patients in clinical diagnosis.
What problem does this paper attempt to address?